ImmunityBio, Inc. (IBRX) Reports Strong Q2 Growth, Eyes Lung Cancer and NMIBC Expansion
ImmunityBio, Inc.
Immunitybio Inc. (IBRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 7,764,000 | $20,496,960 | 0.35% | |
| 2. | Woodline Partners Michael Rockefeller And Karl Kroeker | 3,445,871 | $9,097,099 | +1% | 0.05% |
| 3. | Millennium Management Israel Englander | 3,243,706 | $8,563,384 | +655% | 0% |
| 4. | Tang Capital Management Kevin C. Tang | 2,333,333 | $6,159,999 | 0.31% | |
| 5. | 838,700 | $2,214,168 | +358% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.75 | 485 | $1,333.75 | 71,915 | 2023-06-05 | Filing | |
| $2.77 | 48,000 | $132,960.00 | 71,430 | 2023-06-05 | Filing | |
| $2.72 | 23,430 | $63,729.60 | 23,430 | 2023-06-05 | Filing | |
| $2.90 | 10,000 | $29,000.00 | 25,000 | 2023-06-02 | Filing | |
| $2.80 | 10,000 | $28,000.00 | 15,000 | 2023-06-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.12 | 14,801 | $149,795.00 | 200,617 | 2021-08-23 | Filing | |
| $10.00 | 9,976 | $99,807.88 | 215,418 | 2021-08-20 | Filing | |
| $10.03 | 2,133 | $21,389.08 | 225,394 | 2021-08-18 | Filing | |
| $10.12 | 43,398 | $439,361.35 | 227,527 | 2021-08-17 | Filing | |
| $16.18 | 88,787 | $1,436,822.26 | 3,102,507 | 2021-05-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 633,075 | $1,557,365 | 0.18% | |
| 2. | 560,000 | $1,405,600 | 0.19% | |
| 3. | 519,100 | $1,276,986 | 0.39% | |
| 4. | 306,784 | $754,689 | 0.03% | |
| 5. | 271,456 | $667,782 | 0.02% |
News See All
12 Healthcare Stocks with Insider Buying in 2025
In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, with divergent trends in technology adoption, investment, and fundraising.
11 Best Penny Stocks with the Highest Upside Potential
On September 19, Morningstar released its research report on small-cap stocks as the sector started to rally. The small-cap stocks had largely underperformed the market for over a decade.
ImmunityBio’s (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare penny stocks to buy now. On September 8, 2025, ImmunityBio Inc.
11 Best Healthcare Penny Stocks to Buy Now
The US healthcare sector is one of the biggest in the world, with spending expected to reach $5.3 trillion this year.
H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, H.C. Wainwright reiterated the Buy rating on ImmunityBio, Inc.
12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds
On September 12, Franklin Templeton released its research on active U.S. small-cap management.
ImmunityBio (IBRX) Reports Initial Study Data Showing 100% Disease Control in Patients With Recurrent Glioblastoma
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best long-term penny stocks to buy right now. On August 26, ImmunityBio, Inc.
14 Best Long-Term Penny Stocks to Buy Right Now
On August 29, Ed Yardeni, President of Yardeni Research, appeared on CNBC’s ‘Closing Bell’ to talk about the latest news impacting markets, the possible factors that might inspire the next market...
Hedge Fund Resource Center Billionaire Hedge Funds
